98%
921
2 minutes
20
Background And Purpose: Low-level light therapy (LLLT) has been shown to modulate recovery in patients with traumatic brain injury (TBI). However, the longitudinal impact of LLLT on brain metabolites has not been studied. The purpose of this study was to use magnetic resonance spectroscopic imaging (MRSI) to assess the metabolic response of LLLT in patients with moderate TBI at acute (within 1 week), subacute (2-3 weeks), and late-subacute (3 months) recovery phases.
Materials And Methods: This is a secondary analysis of a prospective single-site double-blinded sham-controlled study conducted in patients with moderate TBI. Participants were randomized for LLLT and sham treatment. Three Tesla two-dimensional MRSI was acquired. Our focus of investigation was the metabolic change in the corpus callosum (CC) and the changes in myo-inositol/N-acetyl aspartate (mI/NAA), representing the combined effect of elevated neuroinflammation (mI) and decreased neuronal/axonal health (NAA). A linear mixed-effects model was constructed to quantify the association between mI/NAA and treatment, scan, and the interaction between treatment and scan.
Results: Thirty-four participants (18 male, age 49±17 (20 to 79); 15 LLLT, 19 sham) were included in the final data set and were scanned at the following timepoints: acute (N=24), subacute (N=27) and late subacute (N=23). The mI/NAA ratio in the CC of the sham-treated participants increased over time. Sham-treated participants revealed a significant increase in mI/NAA from the acute to the late subacute phases (0.19, 95%CI: 0.09, 0.29; p=0.005). mI/NAA stayed relatively stable in participants undergoing LLLT treatment (all p>0.64). Consequently, mI/NAA was significantly higher in the sham-treated participants compared to the LLLT-treated participants during the late subacute phase of recovery (-0.31, 95%CI: -0.50, -0.12; p=0.019).
Conclusions: Despite the small sample size, MRSI indicates a metabolic response in participants treated with LLLT compared to those receiving sham treatment. This potentially suggests a neuroprotective and anti-inflammatory effect from the acute administration of LLLT in individuals with moderate TBI.
Abbreviations: LLLT=Low-level light therapy; TBI=traumatic brain injury; MRSI = magnetic resonance spectroscopic imaging; CC = corpus callosum; mI = in myo-inositol; NAA = N-acetyl aspartate; ATP = adenosine triphosphate; GCS = Glasgow Coma Scale; LASER = Localization by Adiabatic SElective Refocusing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3174/ajnr.A8996 | DOI Listing |
J Autoimmun
September 2025
Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate Member of Freie Un
Objective: New therapeutic options have recently emerged for patients with highly active, acetylcholine receptor antibody-positive (AChR-Ab) generalized myasthenia gravis (gMG), including fast-acting, endplate-protective agents such as complement C5 inhibitors (C5-I) and neonatal Fc receptor inhibitors (FcRn-I). However, objective biomarkers beyond clinical scoring systems are lacking to guide individualized treatment decisions.
Methods: In this exploratory, prospective real-world study, we assessed serum calprotectin (sCLP) and serum neurofilament light chain (sNfL) levels in a total of 22 AChR-Ab gMG patients, who were treatment-naïve for either C5-I or FcRn-I.
Photobiomodul Photomed Laser Surg
September 2025
Department of Oral and Maxillofacial Diagnostic Sciences, Dental College and Hospital, Taibah University, Medina, Saudi Arabia.
Photobiomodulation (PBM) therapy involves the use of low-dose, nonionizing light to reduce pain and inflammation, promote wound healing, and enhance tissue regeneration. PBM-based therapy of various dental conditions is associated with improved treatment outcomes. This study aims to critically review the literature to highlight the underlying molecular biological mechanisms and clinical applications of PBM in modern dental practice.
View Article and Find Full Text PDFJ Am Chem Soc
September 2025
Frontiers Science Center for New Organic Matter, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and Academy for Advanced Interdisciplinary Studies, Nankai University, Tianjin 300071, PR China.
Antigen-capturing nanomaterials hold great promise for cancer immunotherapy; however, the need for tumor localized administration and limited antigen-binding affinity remains the "Achilles heel" of this strategy. Herein, we present a tumor microenvironment (TME)-activatable nanoplatform, TDR848@FPB, designed for systemic administration and enhanced covalent capture of tumor-associated antigens (TAAs), enabling effective immunotherapy with minimal off-target effects and independent of localized tumor administration. This platform encapsulates a photosensitizer-conjugated, light-activated toll-like receptor (TLR) agonist, which induces immunogenic cell death and triggers a pro-inflammatory TME conducive to antigen capture upon light irradiation.
View Article and Find Full Text PDFEur J Clin Microbiol Infect Dis
September 2025
Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.
Purpose: This narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.
Methods: We searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.
Lasers Med Sci
September 2025
Laser Research Center of Dentistry, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Microbial contamination of absorbable collagen membranes used in guided bone regeneration (GBR) may compromise healing outcomes. This study aimed to investigate whether the minimum inhibitory concentration (MIC) of hydrogen peroxide (HO) can improve the antibacterial effect of indocyanine green (ICG)-mediated antimicrobial photodynamic therapy (PDT) on absorbable collagen membranes while reducing the need for high HO concentrations. A laboratory-based model was developed using Streptococcus sanguinis and Staphylococcus aureus.
View Article and Find Full Text PDF